RECENT PLACEMENT

Occam Places Emile Nuwaysir as CEO of Ensoma

Occam Places Emile Nuwaysir as CEO of Ensoma

Ensoma, a 5AM/F-Prime investment, is an in vivo gene editing platform company precisely engineering any or all hematopoietic and immune cells for a one-time, off-the-shelf treatment for a range of debilitating diseases.

In late 2021, Occam recruited Emile Nuwaysir, PhD, as the company’s first CEO. Previously, Emile served as CEO of BlueRock Therapeutics which was acquired by Bayer in 2019 for $1B.

Related Placements

  1. Suzanne “Sue” Bruhn CEO of Prominent Rare Disease Research Foundation
  2. Vatnak Vat-Ho as CBO at Ryvu Therapeutics
  3. Steve Colletti as CSO of Korro Bio
  4. Theo Karaletsos as VP, Data Science/ML at insitro
  5. Sana Hafeez as Head of People at Unlearn
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.